Tela Bio Inc (TELA)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $37.06M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tela Bio Inc (TELA) Earnings: Report Dates and Results
Tela Bio (TELA) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Tela Bio reported EPS of -$0.13, above the -$0.19 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TELA has an expected report date of Mar 22, 2027.
TELA Earnings Call
The latest TELA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, TELA beat 8, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $18.96M, down 8.4% from $20.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.13 | -$0.19 | -$0.21 - -$0.13 | +31.58% | Beat | N/A | 5 | 4 up, 1 down | Nov 10, 2026 | $18.96M |
| Jun 30, 2026 | -$0.20 | -$0.17 | -$0.20 - -$0.15 | -17.65% | Miss | N/A | 5 | 0 up, 1 down | Aug 10, 2026 | $19.29M |
| Mar 31, 2026 | -$0.21 | -$0.15 | -$0.24 - -$0.14 | -39.86% | Miss | N/A | 5 | 1 up, 0 down | May 12, 2026 | $19.06M |
| Dec 31, 2025 | -$0.17 | -$0.18 | -$0.19 - -$0.16 | +5.56% | Beat | N/A | 5 | 1 up, 4 down | Mar 25, 2026 | $20.87M |
| Sep 30, 2025 | -$0.19 | -$0.20 | -$0.22 - -$0.20 | +5.00% | Beat | N/A | 4 | 0 up, 1 down | Nov 13, 2025 | $20.69M |
| Jun 30, 2025 | -$0.22 | -$0.18 | -$0.20 - -$0.18 | -22.22% | Miss | N/A | 4 | 2 up, 2 down | Aug 11, 2025 | $20.20M |
| Mar 31, 2025 | -$0.25 | -$0.21 | -$0.27 - -$0.15 | -19.05% | Miss | N/A | 4 | 2 up, 1 down | May 8, 2025 | $18.52M |
| Dec 31, 2024 | -$0.23 | -$0.22 | -$0.29 - -$0.16 | -3.60% | Miss | N/A | 5 | 2 up, 0 down | Mar 20, 2025 | $17.65M |
| Sep 30, 2024 | -$0.42 | -$0.42 | -$0.44 - -$0.31 | 0.00% | In line | N/A | 5 | 2 up, 0 down | Nov 7, 2024 | $18.96M |
| Jun 30, 2024 | -$0.51 | -$0.47 | -$0.51 - -$0.43 | -8.51% | Miss | N/A | 5 | 0 up, 0 down | Aug 12, 2024 | $16.09M |
| Mar 31, 2024 | -$0.54 | -$0.51 | -$0.53 - -$0.46 | -5.88% | Miss | N/A | 5 | 1 up, 0 down | May 9, 2024 | $16.60M |
| Dec 31, 2023 | -$0.53 | -$0.43 | -$0.46 - -$0.42 | -23.26% | Miss | N/A | 5 | 0 up, 0 down | Mar 21, 2024 | $17.00M |
| Sep 30, 2023 | -$0.45 | -$0.27 | N/A | -66.67% | Miss | N/A | 5 | 0 up, 0 down | Nov 9, 2023 | $15.05M |
| Jun 30, 2023 | -$0.46 | -$0.52 | -$0.58 - -$0.46 | +11.54% | Beat | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | $14.49M |
| Mar 31, 2023 | -$0.63 | -$0.56 | -$0.61 - -$0.49 | -12.50% | Miss | N/A | 5 | 0 up, 0 down | May 11, 2023 | $11.91M |
| Dec 31, 2022 | -$0.52 | -$0.54 | -$0.61 - -$0.49 | +3.70% | Beat | N/A | 5 | 0 up, 0 down | Mar 21, 2023 | $11.62M |
| Sep 30, 2022 | -$0.64 | -$0.56 | -$0.72 - -$0.56 | -14.29% | Miss | N/A | 4 | 0 up, 0 down | Nov 9, 2022 | $11.16M |
| Jun 30, 2022 | -$0.79 | -$0.62 | -$0.69 - -$0.55 | -27.42% | Miss | N/A | 5 | 0 up, 0 down | Aug 10, 2022 | $10.41M |
| Mar 31, 2022 | -$0.75 | -$0.56 | -$0.65 - -$0.44 | -33.93% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2022 | $8.23M |
| Dec 31, 2021 | -$0.59 | -$0.55 | -$0.62 - -$0.45 | -7.27% | Miss | N/A | 4 | 0 up, 0 down | Mar 21, 2022 | $8.37M |
| Sep 30, 2021 | -$0.57 | -$0.52 | -$0.59 - -$0.44 | -9.62% | Miss | N/A | 4 | N/A | Nov 10, 2021 | $7.65M |
| Jun 30, 2021 | -$0.57 | -$0.52 | -$0.56 - -$0.44 | -9.62% | Miss | N/A | 4 | N/A | Aug 11, 2021 | $7.56M |
| Mar 31, 2021 | -$0.56 | -$0.48 | -$0.53 - -$0.37 | -16.67% | Miss | N/A | 4 | N/A | May 13, 2021 | $5.88M |
| Dec 31, 2020 | -$0.54 | -$0.49 | -$0.53 - -$0.42 | -10.20% | Miss | N/A | 4 | N/A | Mar 24, 2021 | $5.67M |
| Sep 30, 2020 | -$0.53 | -$0.48 | -$0.62 - -$0.38 | -10.42% | Miss | N/A | 4 | N/A | Nov 11, 2020 | $5.31M |
| Jun 30, 2020 | -$0.53 | -$0.59 | -$0.67 - -$0.54 | +10.17% | Beat | N/A | 4 | N/A | Aug 12, 2020 | $3.51M |
| Mar 31, 2020 | -$0.63 | -$0.56 | -$0.60 - -$0.53 | -12.50% | Miss | N/A | 4 | N/A | May 12, 2020 | $3.73M |
| Dec 31, 2019 | -$0.57 | -$0.59 | -$0.65 - -$0.57 | +3.39% | Beat | N/A | 4 | N/A | Mar 27, 2020 | $4.86M |
| Sep 30, 2019 | -$0.59 | -$0.45 | -$0.78 - -$0.44 | -31.11% | Miss | N/A | 3 | N/A | Nov 8, 2019 | $3.97M |
| Jun 30, 2019 | -$0.47 | -$0.58 | N/A | +18.97% | Beat | N/A | N/A | N/A | Aug 28, 2019 | $3.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.83, after -$1.70 the year before. It was -$1.63 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.83 | N/A |
| Dec 31, 2024 | -$1.70 | N/A |
| Dec 31, 2023 | -$2.07 | N/A |
| Dec 31, 2022 | -$2.70 | N/A |
| Dec 31, 2021 | -$2.29 | N/A |
| Dec 31, 2020 | -$2.23 | N/A |
| Dec 31, 2019 | -$1.63 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,467 | 9 | |
| 2026Q2 | Jun 30, 2026 | 4,398 | 12 | |
| 2026Q1 | Mar 31, 2026 | 5,551 | 10 | |
| 2025Q4 | Dec 31, 2025 | 8,404 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,249 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,182 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,124 | 8 | |
| 2024Q4 | Dec 31, 2024 | 7,513 | 9 |
2026Q3 Earnings Call
Opening remarks
Louisa Smith Investor Relations Thank you, operator, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Heather Getz, Chief Executive Officer; Jeff Blizard, President; and Jim Hagen, Senior Vice President of Strategic Commercial Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. Heather will begin with the Q3 results and the changes made to strengthen TELA Bio. Jeff will discuss the commercial performance, and then Heather will finish with a review of the financial results in more detail before we take your questions. With that, I'll now turn the call over to Heather.
Heather Getz CEO Good afternoon, everyone, and thank you for joining us. Last week marked my 90th day as CEO of TELA Bio, and I want to use this time not just to walk through our Q3 results, but to share what I've learned, what's already in the process of being changed, and where we're headed. When I joined in August, I made a commitment to our Board, our employees, and all of you that I would listen first, but act swiftly to stabilize the company and extend our runway. Over these past 3 months, I have done just that. I've met with surgeons, investors, and employees across the organization. Three things became clear. First, we believe our core product portfolio is best-in-class at providing both value and performance and is supported by robust clinical data. Even more than I originally appreciated. I will be discussing today additional evidence of OviTex's outstanding clinical profile, which was issued recently. Second, our capital allocation needed to be much more focused. We've been spreading investments across too many initiatives and too quickly without clear prioritization. Third, when we adjusted our go-to-market strategy late last year, we created some gaps that also need to be addressed. The good news is that we have already made meaningful progress on addressing these items, as you will hear today. I'll start with the $17 million cost reduction plan commenced on September 1.
Frequently Asked Questions About TELA
When is Tela Bio's next earnings date?
Tela Bio's next earnings report is expected for Mar 22, 2027.
Did TELA beat earnings estimates last quarter?
Yes. Tela Bio reported EPS of -$0.13 for the quarter ended Sep 30, 2026, above the -$0.19 estimate, a 31.58% surprise.
What EPS do analysts expect from TELA next quarter?
The consensus EPS estimate for Tela Bio for the quarter ending Dec 31, 2026 is -$0.12 from 5 analysts, with estimates from -$0.12 to -$0.12.
How often does TELA beat earnings estimates?
Tela Bio beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -7.53%.
TELA pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts